Group 1 - In the first half of the year, 576 out of 650 comparable QDII funds saw an increase in net value, representing 88.62% of the total [1] - The innovative drug sector has rebounded, leading to significant gains for funds heavily invested in this area, with top performers including Huatai-PB Hong Kong Advantage Selected Mixed Fund A and C, achieving returns of 86.00% and 85.64% respectively [1] - The top ten holdings of the leading funds include companies such as Rongchang Biologics, Kelun Pharmaceutical, and Innovent Biologics, indicating a strong focus on innovative pharmaceuticals [1] Group 2 - Thirteen QDII funds recorded gains exceeding 50% in the first half of the year, with four from E Fund Management, all focused on the innovative drug industry [2] - The top holdings of these high-performing funds include Hansoh Pharmaceutical, Kelun Pharmaceutical, and Innovent Biologics, showcasing a concentrated investment strategy in the healthcare sector [2] - Other ETFs such as GF CSI Hong Kong Innovative Drug ETF and Huatai-PB Hang Seng Innovative Drug ETF also reported gains above 50%, benefiting from the strong performance of the innovative drug sector [2] Group 3 - The top ten holdings of the ICBC New Economy Mixed Fund include Kelun Pharmaceutical, Innovent Biologics, and Hansoh Pharmaceutical, reflecting a strategic focus on high-growth healthcare companies [3] - Funds tracking indices related to Southeast Asian technology and oil sectors have underperformed, indicating sector-specific challenges within the QDII fund landscape [3] Group 4 - The performance rankings of QDII funds show that the top three funds are Huatai-PB Hong Kong Advantage Selected Mixed Fund C, A, and GF CSI Hong Kong Innovative Drug ETF, with net value growth rates of 86.00%, 85.64%, and 57.12% respectively [4] - The bottom-performing funds primarily track indices related to Southeast Asian technology and oil, with significant negative returns [4]

Group 1 - Nearly 80% of the 650 comparable QDII funds saw an increase in net value in the first five months of the year, with 513 funds rising and 135 funds declining [1][2] - The innovative drug sector has rebounded, leading to significant gains for funds heavily invested in this area, with top performers including Huatai-PineBridge Hong Kong Advantage Selection Mixed A and C, achieving returns of 74.12% and 73.69% respectively [1][2] - The top ten holdings of the leading funds include companies such as Rongchang Biologics, Kelun Pharmaceutical, and Innovent Biologics, indicating a strong focus on innovative drugs and high-barrier medical equipment [1][2] Group 2 - Ten QDII funds recorded gains exceeding 40% in the first five months, with four of these funds managed by E Fund, all focusing on the innovative drug sector and achieving returns around 45% [2][3] - Other funds like ICBC New Economy Mixed and Huatai-PineBridge Hang Seng Innovative Drug ETF also reported significant increases, benefiting from the strong performance of the innovative drug sector [2][3] - The funds managed by Yang Zhenshao at E Fund have top holdings including Hansoh Pharmaceutical and Sinopharm, further emphasizing the focus on the pharmaceutical industry [2][3] Group 3 - The bottom-performing QDII funds primarily consist of those focused on oil and gas products, as well as those tracking indices like the S&P Biotechnology Select Industry Index, which have shown poor performance [3][4] - Specific funds such as the E Fund S&P Biotechnology Index C and others in the oil sector have seen declines of over 11% in the same period [3][4]